Imagenebio vs Medicinova
Imagenebio is the larger business, with $800,000 of revenue in fiscal 2025 against $409,657 for Medicinova (2.0 times as much). Medicinova grew faster (-59.0% against -77.1%). Medicinova kept more of each dollar of sales as profit: a net margin of -2928.8% against -5668.6%. Imagenebio carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | ImagenebioIMA, 2025 | MedicinovaMNOV, 2025 |
|---|---|---|
| Revenue | $800,000 | $409,657 |
| Revenue growth | -77.1% | -59.0% |
| Net income | −$45.3m | −$12.0m |
| Operating margin | -6056.4% | -3242.5% |
| Net margin | -5668.6% | -2928.8% |
| Return on equity | — | -23.1% |
| Free cash flow | −$47.8m | −$9.8m |
| Cash | $94.5m | $30.8m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 15 | — |
| Market value | $66.1m | $70.9m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 2 sales | 0 buys, 1 sales |